Coadministration of Tacrolimus and Mycophenolate Mofetil in Stable Kidney Transplant Patients: Pharmacokinetics and Tolerability
Authors:
- Ihor BekerskyIBIhor Bekersky
- Garry BoswellGBGarry Boswell
- E. Steve WoodleEWE. Steve Woodle
- Margaret KruelleMKMargaret Kruelle
- 1 May 2000
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 40 (5) , 527-532
Abstract
The tolerance and pharmacokinetics (PK) of tacrolimus (T) by the addition of mycophenolate mofetil (MMF) in stable kidney transplant patients (6/group) on long‐term tacrolimus‐based therapy were investigated. Patients received combination T and MMF therapy at three MMF doses: 1, 1.5, and 2 g/day administered twice daily. A 12‐hour blood PK profile for T was obtained prior to MMF dosing; concomitant 12‐hour profiles for T, mycophenolic acid (MPA), and mycophenolic acid glucuronide (MPAG) were obtained after 2 weeks of administration. Tolerance was monitored through 3 months. The intra‐ and intergroup PK of T were variable. The mean AUC0–12of T for each group was increased after 2 weeks of concomitant MMF administration, but the increase was not statistically significant. Both drugs were well tolerated. Gastrointestinal events were of interest as such have been attributed to both T and MMF. Events reported were diarrhea, nausea, dyspepsia, and vomiting. Other common adverse events were headache, hypomagnesemia, and tremors. Most were mild, although a few were considered to be moderate. There was no apparent relationship between the incidence of any adverse event and MMF treatment group. In the present study, the coadministration of T and MMF did not significantly alter T pharmacokinetics.Keywords
This publication has 22 references indexed in Scilit:
- Drug Interaction Between Mycophenolate Mofetil and Tacrolimus Detectable Within Therapeutic Mycophenolic Acid Monitoring in Renal Transplant PatientsTherapeutic Drug Monitoring, 1999
- A MULTICENTER TRIAL OF FK506 (TACROLIMUS) THERAPY IN REFRACTORY ACUTE RENAL ALLOGRAFT REJECTIONTransplantation, 1996
- Pharmacokinetics of Oral Mycophenolate Mofetil in Volunteer Subjects with Varying Degrees of Hepatic Oxidative ImpairmentThe Journal of Clinical Pharmacology, 1996
- Pharmacokinetics and Bioavailability of Mycophenolate Mofetil in Healthy Subjects after Single‐Dose Oral and Intravenous AdministrationThe Journal of Clinical Pharmacology, 1996
- Mycophenolate MofetilDrugs, 1996
- Mycophenolic Acid: Measurement and Relationship to Pharmacologie EffectsTherapeutic Drug Monitoring, 1995
- Clinical Pharmacokinetics of TacrolimusClinical Pharmacokinetics, 1995
- Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejectionThe Lancet, 1994
- RS-61443—A PHASE I CLINICAL TRIAL AND PILOT RESCUE STUDY 1Transplantation, 1992
- Clinical Pharmacokinetics of CyclosporinClinical Pharmacokinetics, 1986